Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Finding a new place to work is a job in and of itself, as anyone who’s gone job-seeking in the last three or so years can ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

This was the stock's second consecutive day of losses.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced ...